Successful Treatment of Refractory EBV-Associated Hemophagocytic Lymphohistiocytosis with Combined Emapalumab and PD-1 Blockade

This work was supported by the National Natural Science Foundation of China (82020108003), National Natural Science Foundation of China (81730003), National Key R&D Program of China (2019YFC0840604), Key R&D Program of Jiangsu Province (BE2019798), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Suzhou Science and Technology Program Project (SLT201911) and National Center for Translational Research Open Project (2021ZKMB04), and China Postdoctoral Science Foundation (2023M732540).

留言 (0)

沒有登入
gif